Abstract: A window dressing includes a primary layer having a window for viewing a catheter insertion site. The primary layer includes an adhesive layer on a lower, skin-contacting face of the primary layer. A transparent layer covers the window and adheres to the upper surface of the primary layer. An ultrasonic transmission layer is positioned below the primary layer, where the transmission layer comprises a layer of hydrogel. A support structure has a stiffness that is greater than the primary layer and has an adhesive layer on the lower surface of the support structure. The support structure adhesive layer adheres the support structure to the upper surface of the primary layer.

Abstract: A window dressing includes a primary layer having a window for viewing a catheter insertion site. The primary layer includes an adhesive layer on a lower, skin-contacting face of the primary layer. A transparent layer covers the window and adheres to the upper surface of the primary layer. An ultrasonic transmission layer is positioned below the primary layer, where the transmission layer comprises a layer of hydrogel. A support structure has a stiffness that is greater than the primary layer and has an adhesive layer on the lower surface of the support structure. The support structure adhesive layer adheres the support structure to the upper surface of the primary layer.

Abstract: A window dressing includes a primary layer having a window for viewing a catheter insertion site. The primary layer includes an adhesive layer on a lower, skin-contacting face of the primary layer. A transparent layer covers the window and adheres to the upper surface of the primary layer. An ultrasonic transmission layer is positioned below the primary layer, where the transmission layer comprises a layer of hydrogel. A support structure has a stiffness that is greater than the primary layer and has an adhesive layer on the lower surface of the support structure. The support structure adhesive layer adheres the support structure to the upper surface of the primary layer.

Abstract: Methods and compositions for reducing, preventing or reducing the progression of calcification in peritoneal dialysis patients are provided. In an embodiment, the present disclosure provides a method comprising administering to a patient during peritoneal dialysis therapy a dialysis solution comprising a therapeutically effective amount of pyrophosphate ranging between about 30 ?M and about 400 ?M. Formulations of dialysis solutions according to the dose ranges claimed in the present disclosure allow therapeutic amounts of pyrophosphate to be delivered to peritoneal dialysis patients.

Abstract: Methods and compositions for reducing, preventing or reducing the progression of calcification in peritoneal dialysis patients are provided. In an embodiment, the present disclosure provides a method comprising administering to a patient during peritoneal dialysis therapy a dialysis solution comprising a therapeutically effective amount of pyrophosphate ranging between about 30 ?M and about 400 ?M. Formulations of dialysis solutions according to the dose ranges claimed in the present disclosure allow therapeutic amounts of pyrophosphate to be delivered to peritoneal dialysis patients.

Abstract: The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.

Abstract: The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.

Abstract: The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.

Abstract: Disclosed are 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythromycin A derivatives which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.

Abstract: The present invention relates to novel substituted piperidine derivatives of formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

Abstract: The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula (1): and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

Abstract: Disclosed are 3'-N-desmethyl-3'-N-susbstituted-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythrolide A derivatives which are antagonists of luteinizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.

Abstract: Disclosed are 3',3'-N-bisdesmethyl-3',3'-N-bis-substituted-6-O-methyl-11-deoxy-11,12-cyc lic carbamate erythromycin A derivatives which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.

Abstract: Disclosed are 3'-N-desmethyl-3'-N-substituted-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythromycin A derivatives which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.

Abstract: The present invention relates to novel N-methyl-N-(4-(4-(1H-benzimidazol-2-yl)?1,4!diazepan-1-yl)-2-(aryl)butyl)b enzamide derivatives of the formula: ##STR1## stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

Abstract: The present invention relates to novel benzenesulfonylimine derivatives and their use as inhibitors of Interleukin-1 (IL-1) action. Such inhibitors are useful in the treatment of various disease states as disclosed herein including: rheumatoid arthritis, multiple sclerosis, diabetes mellitus, atherosclerosis, septic shock and pulmonary fibrosis.